0.98
-0.0023(-0.23%)
Currency In USD
| Previous Close | 0.99 |
| Open | 1.01 |
| Day High | 1.02 |
| Day Low | 0.95 |
| 52-Week High | 3.1 |
| 52-Week Low | 0.85 |
| Volume | 95,677 |
| Average Volume | 175,414 |
| Market Cap | 16.93M |
| PE | -0.64 |
| EPS | -1.54 |
| Moving Average 50 Days | 1.46 |
| Moving Average 200 Days | 1.46 |
| Change | -0 |
If you invested $1000 in Unity Biotechnology, Inc. (UBX) since IPO date, it would be worth $5.91 as of April 25, 2025 at a share price of $0.984. Whereas If you bought $1000 worth of Unity Biotechnology, Inc. (UBX) shares 5 years ago, it would be worth $14.59 as of April 25, 2025 at a share price of $0.984.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed jo
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
GlobeNewswire Inc.
Mar 24, 2025 11:01 AM GMT
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-infe
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
GlobeNewswire Inc.
Mar 23, 2025 8:00 PM GMT
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virt